anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The main purpose of this study is to determine the effectiveness of using an oral supplementation of alpha lipoid acid to improve clinical and electrophysiological recovery after carpal tunnel release surgery. This research is designed as a double blinded clinical trial, with a calculated sample size of 40 patients, divided in two groups of 20 (A placebo, B alpha lipoid acid). All patients will undergo open carpal tunnel release surgery, the procedure will be performed by an expert surgeon. A total of four visits will be performed as follows: T0. baseline 4 weeks before surgery, T1 immediately before surgery, T2: 4 weeks after surgery, T3: 8 weeks after surgery, T4: 12 weeks after surgery. The assessment to be perform on each visit includes: physical examination, Boston Questionary for Carpal Tunnel Syndrome. Nerve conduction study and ecographic evaluation will be performed on visits T0, T1 and T4. Statistical Analysis: Categorical variables will be assessed as counts and percent frequency and compared using the chi-squared test. All statistical analyses will be performed using the SPSS 21.0 package (SPSS Inc., Chicago, IL, USA). A two-tailed P value \< 0.05 was considered statistically significant.
To (i) determine whether accelerated long-term forgetting (ALF) can be found using standardized verbal memory test materials in children with genetic generalized epilepsy (GGE) and temporal lobe epilepsy (TLE), and (ii) to establish whether ALF is impacted by executive skills and repeat testing over long delays. One hundred and twenty-three children aged 8 to 16, (28 with GGE, 23 with TLE, and 72 typically developing; TD) completed a battery of standardized tests assessing executive functioning and memory for two stories. Stories were recalled immediately and after a 30-min delay. To examine whether repeat testing impacts long-term forgetting, one story was tested via free recall at 1-day and 2-weeks, and the other at 2-weeks only. Recognition was then tested for both stories at 2-weeks. Children with epilepsy recalled fewer story details, both immediately and after 30-min relative to TD children. Compared to TD children, the GGE group, but not the TLE group, showed ALF, having significantly poorer recall of the story tested only at the longest delay. Poor executive skills were significantly correlated with ALF for children with epilepsy. Standard story memory materials can detect ALF in children with epilepsy when administered over long delays. Our findings suggest that (i) ALF is related to poor executive skills in children with epilepsy, and (ii) repeated testing may ameliorate ALF in some children.
Depressive disorders have increased in global prevalence, making improved management of these disorders a public health priority. Prior research has linked circadian clock genes to depression, either through direct interactions with mood-related pathways in the brain or by modulating the phase of circadian rhythms. Using machine learning and statistical techniques, we explored associations between 157,347 SNP variants from 51 circadian-related genes and depression scores from the patient health questionnaire 9 (PHQ-9) in 99,939 UK Biobank participants. Our results highlight multiple pathways linking the circadian system to mood, including metabolic, monoamine, immune, and stress-related pathways. Notably, genes regulating glucose metabolism and inflammation (GSK3B, LEP, RORA, and NOCT) were prominent factors in females, in addition to DELEC1 and USP46, two genes of unknown function. In contrast, FBXL3 and DRD4 emerged as significant risk factors for male depression. We also found epistatic interactions involving RORA, NFIL3, and ZBTB20 as either risk or protective factors for depression, underscoring the importance of transcription factors (ZBTB20, NFIL3) and hormone receptors (RORA) in depression etiology. Understanding the complex, sex-specific links between circadian genes and mood disorders will facilitate the development of therapeutic interventions and enhance the efficacy of multi-target treatments for depression.
Initiate treatment at ages 5 weeks to 5 months.

The recommended starting dose of HEMANGEOL is 0.15 mL/kg (0.6 mg/kg) (see Table 1) twice daily, taken at least 9 hours apart. After 1 week, increase the daily dose to 0.3 mL/kg (1.1 mg/kg) twice daily. After 2 weeks of treatment, increase the dose to 0.4 mL/kg (1.7 mg/kg) twice daily and maintain this for 6 months. Readjust the dose periodically as the child’s weight increases.

To reduce the risk of hypoglycemia, administer HEMANGEOL orally during or right after a feeding. Skip the dose if the child is not eating or is vomiting [see Warnings and Precautions (5.1)] . 

Monitor heart rate and blood pressure for 2 hours after HEMANGEOL initiation or dose increases [see Warnings and Precautions (5.2)]. 

If hemangiomas recur, treatment may be re-initiated [see Clinical Studies (14)] . 

HEMANGEOL is supplied with an oral dosing syringe for administration. Administration directly into the child’s mouth is recommended. Nevertheless, if necessary, the product may be diluted in a small quantity of milk or fruit juice, given in a baby’s bottle.

Table 1. Dose Titration According to Weight
The present disclosure relates exposure notification, and in particular to techniques for verification of positive test results from public health authorities where individuals submit notice using public health approved mobile applications for exposure notification and/or contact tracing. When an individual attempts to submit a positive test result notification in a mobile application, the associated device's mobile number will be requested. This mobile number will then be sent a verification code to be entered in the application. At this point, these codes shall be stored digitally in escrow. A regular data feed from a health authority shall be provided that shall include an agreed encryption (irreversibly encrypted or reversibly encrypted) of the mobile numbers associated with any reported test. Any results submitted in the application that have a matching encryption of the mobile numbers shall be released from the escrow for subsequent notification.
PURPOSE: An aerosol foundation cosmetic composition is provided to ensure visual difference and freshness in use. CONSTITUTION: An aerosol foundation cosmetic composition contains 70-95 weight% of oil-in-water foundation as crude aerosol liquid and remaining amount of aerosol dispersion agent. The crude aerosol liquid contains 0.01-5 weight% of water-soluble inorganic thickener, 1-10 weight% of oxidant as a coloring agent, 1-10 weight% of silicon oil and 0.1-10 weight% of emulsion as oil phase part, 0.1-10 weight% of cetanol as fatty acid alcohol of high quality, 1-10 weight% of ethanol as cooling agent, 0.1-3 weight% of skin astringent, and remaining amount of solvent. The water-soluble inorganic thickener is hydroxypropylmethylcellulose, xanthangum, sodium magnesium silicate or their mixture. The oxidant is ferric oxide, titanium oxide, or their mixture. The silicon oil is dimethicone, phenyldimethicone or their mixture. The emulsion is surfactant, triethanolamine or their mixture. The skin astringent is menthol lactate.
PCT No. PCT/US94/14388 Sec. 371 Date Sep. 25, 1997 Sec. 102(e) Date Sep. 25, 1997 PCT Filed Dec. 9, 1994 PCT Pub. No. WO96/17931 PCT Pub. Date Jun. 13, 1996A human Vascular IBP-like growth factor polypeptide (VIGF) and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for wound healing or tissue regeneration, stimulating implant fixation and angiogenesis. Antagonists against such polypeptides and their use as a therapeutic to treat atherosclerosis, tumors and scarring are also disclosed. Diagnostic assays for identifying mutations in VIGF nucleic acid sequences and altered levels of the VIGF polypeptide are also disclosed.
Inactive Ingredients: Hydrogenated vegetable oil, magnesium stearate, polyethylene glycol, polyvinyl alcohol, silicon dioxide, talc and titanium dioxide. Yellow tablets also contain D&C Yellow No. 10 aluminum lake and FD&C Yellow No. 6 aluminum lake. Blue tablets also contain FD&C Blue No. 1 aluminum lake and FD&C Blue No. 2 aluminum lake.
PURPOSE:To obtain the titled composition by extracting a crude drug with water, a primary alcohol, etc., separating the extract into an essence and the residue, concentrating the essence so that it is dried by adsorbing it to the residue, and packing it alove or together with and components of hot spring in paper, cloth, etc., to give a bathing agent. CONSTITUTION:A crude drug (e.g., Japanese angelica root, Cnidium, Matricaria chamomilla L., mint, rosemary) is extracted with water, hot water, or primary alcohol (e.g., ethanol) once or several times, separated by suction filtration, etc. into an extracted essence and the extracted residue, the extracted essence is evaporated under heating, and concentrated by condensation under reduced pressure, etc. The prepared concentrated essence is adsorbed on the extracted residue by operations such as imgregnation, spray, etc., and dried to give the titled composition. This compostion alone or it and ingredients of hot spring (e.g., Na2SO4, NaCl) are blended in an arbitrary ratio, packed into a permeable container like tea bag, such as paper, nonwoven fabric, cloth, etc., contg. 10- 100g for one use, and sealed with an adhesive, thermal welding, sewing, etc., to give a bathing agent.
NPMP is a body-mind awareness approach, often given in a combination of massage, exercises and conversations. The NPMP is individualized, with duration of 45-60 minutes in each session. As the NPMP is a longitudinal and normally slow process to obtain change, treatment can last up till one year, in the beginning once a week, and after some time once a month.
In case of life-threatening, serious or overwhelming malaria infections due to P. falciparum, patients should be treated with an intravenous antimalarial drug. Following completion of intravenous treatment, mefloquine may be given to complete the course of therapy.

Halofantrine should not be administered with mefloquine or within 15 weeks of the last dose of mefloquine due to the risk of a potentially fatal prolongation of the QTc interval (see CLINICAL PHARMACOLOGY: Pharmacokinetics: Elimination).

Ketoconazole should not be administered with mefloquine or within 15 weeks of the last dose of mefloquine due to the risk of a potentially fatal prolongation of the QTc interval. Ketoconazole increases plasma concentrations and elimination half-life of mefloquine following co-administration (see CLINICAL PHARMACOLOGY: Pharmacokinetics: Elimination and PRECAUTIONS: Drug Interactions).

Mefloquine may cause psychiatric symptoms in a number of patients, ranging from anxiety, paranoia, and depression to hallucinations and psychotic behavior. On occasions, these symptoms have been reported to continue long after mefloquine has been stopped. Rare cases of suicidal ideation and suicide have been reported though no relationship to drug administration has been confirmed. To minimize the chances of these adverse events, mefloquine should not be taken for prophylaxis in patients with active depression or with a recent history of depression, generalized anxiety disorder, psychosis, or schizophrenia or other major psychiatric disorders. Mefloquine should be used with caution in patients with a previous history of depression.

During prophylactic use, if psychiatric symptoms such as acute anxiety, depression, restlessness or confusion occur, these may be considered prodromal to a more serious event. In these cases, the drug must be discontinued and an alternative medication should be substituted.

Concomitant administration of mefloquine and quinine or quinidine may produce electrocardiographic abnormalities.

Concomitant administration of mefloquine and quinine or chloroquine may increase the risk of convulsions.
PURPOSE:To obtain the titled composition storable stably for a long period, by adding baicalin or baicalein useful as an antiallergic agent to a mixture of water and alcohol in the presence of a solubilizing stabilizer consisting of a specific amino acid and sugar or acid amide compound. CONSTITUTION:The objective composition can be prepared by adding (A) 0.1- 0.6% baicalin of formula I or baicalein of formula II and (B) a solubilizing stabilizer consisting of (i) 0.1-1.2% amino acid (containing at least proline) and 0.1- 1.2% sugar (containing at least saccharose) or (ii) 0.1-1.2% acid amide compound (e.g. nicotinamide, thioctamide, urea, etc.) to (C) a 1:1 mixture of water and propylene glycol (or butylene glycol or ethanol). A composition which can be dissolved stably for a long period is prepared without using a surfactant, etc., by the use of the above solubilizing stabilizer. The agent is effective to allergic diseases, urticaria, itchiness, etc.
Decreased BMD and bone loss is estimated to affect up to 67.5% of the HIV-infected population. HIV-associated bone loss may be a result of antiretroviral treatment (ART), but can also be caused by the infection itself. To date, treatment for this bone loss has not been established. Before prescribing drugs to treat bone loss, physicians must take into account patients' already demanding ART schedules and potential nonadherence. This study will evaluate the efficacy of a single IV dose of zoledronate, an investigational bisphosphonate, in treating HIV-associated bone loss.

This study will last 1 year. Participants will be randomly assigned to receive zoledronate or placebo at study entry; their assigned intervention will be given in a 20- to 30-minute infusion on an outpatient basis. There will be 7 study visits: at screening, study entry, Week 2, and Months 3, 6, 9, and 12. Blood collection will occur at all visits. Medical history, a physical exam, a dual-energy x-ray absorptiometry (DEXA) scan to measure bone density, and a nutrition evaluation will occur at selected visits.
Cerebral small vessel disease (SVD) is commonly detected in elderly individuals, and patients with stroke or neurodegenerative disease. Features seen on neuroimaging include recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, and brain atrophy. Previous studies indicated that SVD was associated with an increased risk of stroke and stroke recurrence, cognitive deficits, physical disabilities, and mortality. However the pathogenesis of SVD is largely unknown. Little is known about how SVD lesions contribute to neurological or cognitive symptoms, and the association with risk factors. Recent data sugessted concomitant SVDs and retinopathy is associated with a profile of vascular cognitive impairment. In this study, the investigators try to explore the new pathological mechanism of SVD, the new predictors for SVD progression, and the association with cognitive Impairment, based on digital retinal images and brain multimodal imaging technique.
The purpose of the proposed project is to investigate the effectiveness of Equine Assisted Learning (EAL) for reducing symptoms related to PTSD among public safety personnel. EAL is an intervention in which mental health clinicians and equine specialists work together with clients to address a learning goal via unmounted interaction with a horse. Recent literature indicates that EAL shows promise in addressing a range of mental health diagnoses among a variety of populations, including military and Royal Canadian Mounted Police veterans with PTSD. The EAL intervention will be delivered at Cartier Farms in Spruce Home, Saskatchewan. Research components of this study will be conducted virtually via Zoom.

The investigators will employ a randomized controlled trial design with pre-post and follow-up testing. Participants will be randomized into one of two groups: the intervention group will receive the EAL intervention for 8 weeks while waitlist control condition will not receive this treatment for the same amount of time. Data on PTSD symptom severity will be collected from all participants prior to the start of the EAL intervention (baseline), again within two weeks after the EAL intervention is complete (post), and then a final time three months after the EAL intervention ends (follow-up). The two groups will then be compared to determine whether there are differences in PTSD symptom severity between groups. To obtain a sufficient sample size while also running appropriately sized EAL groups of 10 per session, the investigators will conduct four rounds of randomization, Thus, the final sample size will be 80 (40 in the intervention condition and 40 in the waitlist control condition). All individuals in the waitlist control condition will be offered EAL following their completion of the study.
Prehabilitation Group received the same protocol as Group B, however in addition they were prehabilitated with a water-filled stoma pouch (250 ml) 48 hours before surgery. These pouches were not removed until surgery, and EST nurse preoperatively taught the patients how to manage the stoma pouch with similar standards as the usual postoperative stoma-care.
This report discusses a case of transient 2:1 atrioventricular block with conduction system pacing 4 hours after leadless right ventricular pacemaker implantation in a 19-year-old patient with a history of cardioinhibitory syncope and asystole cardiac arrest but without preexisting atrioventricular block. The atrioventricular block was resolved spontaneously. Pacing morphology was suggestive of right bundle branch pacing. Neither 2:1 atrioventricular block nor conduction system pacing has previously been a reported outcome of right ventricular leadless pacemaker implantation. The report demonstrates that conduction system pacing with leadless devices is achievable. Further study of techniques, limitations, and complications related to intentional right ventricular leadless conduction system pacing is warranted.
A medicinal preparation, particularly for the treatment of piles, is obtained by heating rock alum in a crucible or kiln at about 106 DEG F. until a scum or efflorescence is formed on the surface of the lumps, removing said efforescence, and powdering the lumps.  During the heat treatment, the mass of the material is reduced by 8-10 per cent; it is believed that the efflorescence contains impurities.  The powder may be taken internally in milk or water, or may be applied externally as a powder or combined with binding or agglutinant means. It may also be dissolved, and applied as a lotion.ALSO:A medicinal preparation, particularly for the treatment of piles, is obtained by heating rock alum in a crucible or kiln at about 106 DEG  F. until a scum or efflorescence is formed on the surface of the lumps, removing said efflorescence, and powdering the lumps.  During the heat treatment, the mass of the material is reduced by 8-10 per cent.; it is believed that the efflorescence contains impurities.  The powder may be taken internally in milk or water, or may be applied externally as a powder or combined with binding or agglutinant means. It may also be dissolved, and applied as a lotion.
The purpose of this study is to develop and test the acceptability, feasibility, and preliminary efficacy of two brief online writing interventions to improve parental acceptance of sexual and gender minority youth (SGMY) in the Southeast United States. Parental support represents the strongest predictor of sexual and gender minority youth's (SGMY) mental health. However, many parents react to their SGMY's disclosure with rejection. Even relatively accepting parents can experience discomfort, while SGMY often report lingering unmet needs from their parents into adulthood. Few interventions exist to help parents support their SGMY child and none has been tested in a randomized trial with efficacy for decreasing parental rejection and increasing support of their SGMY. This proposal will develop and test the efficacy of two theory-based interventions that aim to address this gap. Results will identify mechanisms contributing to parental rejection and develop scalable approaches to reduce these mechanisms to shrink the substantial mental health disparities affecting SGMY. If efficacious, these interventions can be scaled up through online platforms capable of bypassing barriers to parental support of SGMY across high-stigma regions.

The focus of this registration is the randomized controlled trial.
The present invention relates to 1) pharmaceutical compositions and methods for chemotherapeutic agents and 2) pharmaceutical compositions for biological agents, particularly those whose target cells or tissues are resistant to the biological agent. The invention is targeted to overcome the resistance to biological agents that are developed by neoplasms and microbial infections. The formulation contains a biological agent and a polyether block copolymer. The block copolymer comprises an A-type linear polymeric segment joined at one end to a B-type linear polymeric segment; wherein the A type polymeric segment is hydrophilic, has repeating units which contribute an average Hansch-Leo fragmental constant of about 0.4 or less, and has a molecular weight contribution between 30 to about 500. The B-type segment is of relatively hydrophobic character, has repeating units which contribute an average Hansch-Leo fragmental constant of about -0.4 or more and a molecular weight contribution of about 30 to about 500, and has repeating units for each polymeric segment that comprise an ether linkage. The compositions may comprise chemotherapeutic agents, cytotoxic drugs, microbial treating agents, and a second biological agent.
The invention discloses a composition for preventing and treating prostate diseases and a preparation method thereof. The composition for preventing and treating prostate diseases takes freeze-dried rape bee pollen, raspberry freeze-dried powder, zinc-rich yeast, arginine and aescin powder as main raw materials. By combining modern scientific technology and processing the rape bee pollen in a pulse electric field wall breaking mode, a layer of bee pollen cell has certain resistance to acid, alkali, high temperature and high pressure processing, the outer wall is broken, the intracellular substances are quickly released, the nutrient components of the raw materials are better reserved, and the absorption by a human body is facilitated. The organic synthetic zinc is adopted as the raw material of the zinc-rich yeast, so that the irritation to intestines and stomach is small, and the zinc-rich yeast can be better absorbed by human bodies. Meanwhile, the aescin powder is added to improve the symptoms of frequent micturition, urgent micturition and urge incontinence. Can effectively prevent and treat prostate diseases.
FIELD: chemistry. ^ SUBSTANCE: described is novel compound of formula (I) ^ or its pharmaceutically acceptable salt, values of radicals are given in invention formula Compound has ability to inhibit receptor mGluR5, which intends it for prevention and/or treatment of receptor mGluR5- associated disturbances. Also described is pharmaceutical composition, method of inhibiting activation of receptors mGluR5, using compound of formula (I). Described is method of obtaining compound of formula 1a or 1b structure. ^ EFFECT: increasing output of suitable product. ^ 18 cl, 825 ex
A daily dose of clobazam greater than 5 mg should be administered in divided doses twice daily; a 5 mg daily dose can be administered as a single dose. Dose patients according to body weight. Individualize dosing within each body weight group, based on clinical efficacy and tolerability. Each dose in Table 1 (e.g., 5 to 20 mg in ≤30 kg weight group) has been shown to be effective, although effectiveness increases with increasing dose [see Clinical Studies (14)] . Do not proceed with dose escalation more rapidly than weekly, because serum concentrations of clobazam and its active metabolite require 5 and 9 days, respectively, to reach steady-state. 

Table 1. Recommended Total Daily Dosing by Weight Group